Sun Pharma deals include the $230 million purchase of US-based dermatology specialist Dusa Pharmaceuticals and $450 million in Israel's Taro Pharmaceutical Industries (Representational Image) Mumbai: Sun Pharmaceuticals Industries, emboldened by ... Deccan Chronicle, 5 days ago
Sun Pharmaceuticals Industries, emboldened by its takeover of domestic rival Ranbaxy Laboratories, is willing to spend as much as $7 billion on further acquisitions, bankers familiar with the generic drugmaker's strategy said. The just completed ...Financial Chronicle, 5 days ago Sun Pharma lines up $7b for M&As Oman Tribune, 5 days ago Sun Pharma scouting for more deals; may spend $7bn Economic Times, 5 days ago Sun Pharmaceutical may spend $7 bn on M&A Business Today India, 5 days ago
Dilip Sanghvi led Sun Pharmaceutical Industries is acquiring GlaxoSmithKline's Australian opiates business. The financial details of the deal remain undisclosed. The buy consists of two manufacturing sites, one each in Latrobe (Tasmania) and Port ...Deal Curry, 2 months ago
Generic Drugs a $350 Billion Opportunity According to 'The Generic Drugs Market: 2015-2030 - Opportunities, Challenges, Strategies & Forecasts'
A generic drug is a pharmaceutical product, usually intended to be interchangeable with an innovator product, that is manufactured without a license from the innovator company and marketed after the expiry date of the patent or other exclusive ...Morningstar.com, 2 months ago
Dilipbhai, as his friends and industry associates address him, is not much of a social mover and shaker. His only indulgence perhaps is an occasional visit to Matunga — Mumbai's South India — to gorge on sumptuous dosas at the famous Mysore Cafe ...Businessworld India, 5 days ago
0 Flares 0 Flares × KISSIMMEE, FLA. (FRONTLINE MEDICAL NEWS) Fractional carbon dioxide laser resurfacing followed by 30 minutes of aminolevulinic acid plus blue light photodynamic therapy cleared 94% of actinic keratoses, significantly ...PM 360, 6 days ago
Biofrontera AG ("Biofrontera" or "Company" or "Group) Leverkusen, Germany, 10 April 2015 - Biofrontera AG (FSE/AIM:B8F), the biopharmaceutical company focusing on skin cancer, announces final results for the year ended 31 December 2014. ...TrustNet, 3 weeks ago
ets are expected to open in the red tracking the SGX Nifty and weak global cues. US markets closed sharply lower led by a sell-off in technology and biotech stocks. The Commerce Department also released a report showing an unexpected drop in ...Stock Markets Review, 1 month ago
MUMBAI: Following the successful closure of the $3.2 billion merger with troubled drug maker Ranbaxy, Dilip Shanghvi-led Sun Pharma said on Wednesday that the company is initiating the integration of the business, which will make the combined entity ...Times of India, 1 month ago
Summit Corporation plc Summit Therapeutics plc ('Summit' or the 'Company') SUMMIT APPOINTS MR DAVID WURZER AS NON-EXECUTIVE DIRECTOR Oxford, UK, 23 February 2015 - Summit Therapeutics plc (AIM: SUMM), the drug discovery and development ...4 Traders, 1 month ago
on your WebpageAdd Widget >Get your members hooked!